Tyler Van Buren
Stock Analyst at TD Cowen
(1.60)
# 3,189
Out of 4,843 analysts
56
Total ratings
39.13%
Success rate
-6.11%
Average return
Main Sectors:
Stocks Rated by Tyler Van Buren
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CGON CG Oncology | Initiates: Buy | n/a | $25.63 | - | 1 | Jan 7, 2025 | |
| KROS Keros Therapeutics | Downgrades: Hold | n/a | $14.15 | - | 2 | Dec 12, 2024 | |
| BHVN Biohaven | Maintains: Buy | $55 → $75 | $14.81 | +406.41% | 2 | Nov 13, 2024 | |
| BCAX Bicara Therapeutics | Initiates: Buy | n/a | $9.25 | - | 1 | Oct 8, 2024 | |
| ORKA Oruka Therapeutics | Initiates: Buy | n/a | $10.95 | - | 1 | Sep 16, 2024 | |
| MRNA Moderna | Maintains: Hold | $70 → $60 | $26.56 | +125.90% | 6 | Sep 13, 2024 | |
| ARTV Artiva Biotherapeutics | Initiates: Buy | n/a | $1.93 | - | 1 | Aug 13, 2024 | |
| RNAC Cartesian Therapeutics | Initiates: Buy | n/a | $9.56 | - | 1 | Aug 6, 2024 | |
| REGN Regeneron Pharmaceuticals | Maintains: Buy | $1,030 → $1,200 | $490.28 | +144.76% | 7 | Jul 23, 2024 | |
| TECX Tectonic Therapeutic | Initiates: Buy | n/a | $21.53 | - | 1 | Jun 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | n/a | $18.11 | - | 1 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $90 → $85 | $110.08 | -22.78% | 5 | Apr 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $30 | $36.29 | -17.33% | 2 | Dec 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $4.23 | - | 1 | Dec 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $15.27 | - | 1 | Nov 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $62.06 | - | 1 | Oct 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $36.62 | - | 1 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $30 | $15.02 | +99.73% | 1 | May 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $34.25 | - | 1 | Feb 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.21 | - | 2 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $70 | $36.50 | +91.78% | 1 | Aug 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $1.22 | - | 1 | Jul 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $7.20 | - | 1 | Dec 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $9.10 | - | 1 | Oct 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $50 | $1.68 | +2,876.19% | 1 | Mar 4, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $875 | $5.29 | +16,440.64% | 1 | Nov 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $40 | $3.97 | +907.56% | 1 | Aug 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $40 | $10.63 | +276.29% | 1 | Aug 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $35 → $30 | $9.20 | +226.09% | 3 | Aug 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $60 | $0.38 | +15,773.02% | 1 | Jun 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $50 | $1.35 | +3,603.70% | 1 | Jun 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $1.11 | +2,602.70% | 1 | Apr 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $140 → $200 | $2.22 | +8,929.35% | 1 | Jan 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $3.09 | - | 1 | Nov 2, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $16.78 | - | 1 | Aug 4, 2017 |
CG Oncology
Jan 7, 2025
Initiates: Buy
Price Target: n/a
Current: $25.63
Upside: -
Keros Therapeutics
Dec 12, 2024
Downgrades: Hold
Price Target: n/a
Current: $14.15
Upside: -
Biohaven
Nov 13, 2024
Maintains: Buy
Price Target: $55 → $75
Current: $14.81
Upside: +406.41%
Bicara Therapeutics
Oct 8, 2024
Initiates: Buy
Price Target: n/a
Current: $9.25
Upside: -
Oruka Therapeutics
Sep 16, 2024
Initiates: Buy
Price Target: n/a
Current: $10.95
Upside: -
Moderna
Sep 13, 2024
Maintains: Hold
Price Target: $70 → $60
Current: $26.56
Upside: +125.90%
Artiva Biotherapeutics
Aug 13, 2024
Initiates: Buy
Price Target: n/a
Current: $1.93
Upside: -
Cartesian Therapeutics
Aug 6, 2024
Initiates: Buy
Price Target: n/a
Current: $9.56
Upside: -
Regeneron Pharmaceuticals
Jul 23, 2024
Maintains: Buy
Price Target: $1,030 → $1,200
Current: $490.28
Upside: +144.76%
Tectonic Therapeutic
Jun 24, 2024
Initiates: Buy
Price Target: n/a
Current: $21.53
Upside: -
May 15, 2024
Initiates: Buy
Price Target: n/a
Current: $18.11
Upside: -
Apr 26, 2024
Maintains: Buy
Price Target: $90 → $85
Current: $110.08
Upside: -22.78%
Dec 11, 2023
Downgrades: Underperform
Price Target: $30
Current: $36.29
Upside: -17.33%
Dec 5, 2023
Initiates: Outperform
Price Target: n/a
Current: $4.23
Upside: -
Nov 29, 2023
Initiates: Outperform
Price Target: n/a
Current: $15.27
Upside: -
Oct 30, 2023
Initiates: Outperform
Price Target: n/a
Current: $62.06
Upside: -
Aug 8, 2023
Initiates: Outperform
Price Target: n/a
Current: $36.62
Upside: -
May 22, 2023
Initiates: Outperform
Price Target: $30
Current: $15.02
Upside: +99.73%
Feb 6, 2023
Initiates: Outperform
Price Target: n/a
Current: $34.25
Upside: -
Jan 6, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $1.21
Upside: -
Aug 8, 2022
Initiates: Outperform
Price Target: $70
Current: $36.50
Upside: +91.78%
Jul 12, 2022
Initiates: Outperform
Price Target: n/a
Current: $1.22
Upside: -
Dec 7, 2021
Initiates: Outperform
Price Target: n/a
Current: $7.20
Upside: -
Oct 11, 2021
Initiates: Outperform
Price Target: n/a
Current: $9.10
Upside: -
Mar 4, 2021
Initiates: Overweight
Price Target: $50
Current: $1.68
Upside: +2,876.19%
Nov 10, 2020
Initiates: Overweight
Price Target: $875
Current: $5.29
Upside: +16,440.64%
Aug 18, 2020
Initiates: Overweight
Price Target: $40
Current: $3.97
Upside: +907.56%
Aug 18, 2020
Initiates: Overweight
Price Target: $40
Current: $10.63
Upside: +276.29%
Aug 10, 2020
Maintains: Overweight
Price Target: $35 → $30
Current: $9.20
Upside: +226.09%
Jun 29, 2020
Initiates: Overweight
Price Target: $60
Current: $0.38
Upside: +15,773.02%
Jun 29, 2020
Initiates: Overweight
Price Target: $50
Current: $1.35
Upside: +3,603.70%
Apr 22, 2020
Initiates: Overweight
Price Target: $30
Current: $1.11
Upside: +2,602.70%
Jan 13, 2020
Reiterates: Overweight
Price Target: $140 → $200
Current: $2.22
Upside: +8,929.35%
Nov 2, 2017
Downgrades: Market Perform
Price Target: n/a
Current: $3.09
Upside: -
Aug 4, 2017
Downgrades: Market Perform
Price Target: n/a
Current: $16.78
Upside: -